Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule.

It will be used in the upcoming Phase 1 clinical trial assessing the treatment of Alcohol Use Disorder (AUD).

"Like other addictions, AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use," Clearmind’s CEO Dr. Adi Zuloff-Shani said. "Alcohol abuse is the third-most-common preventable cause of death in the US, where almost 6% …

Full story available on